A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs Temozolomide (Primary) ; Veliparib (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 27 May 2019 Planned primary completion date changed from 30 Jun 2022 to 14 Jun 2021.
- 31 Aug 2018 Biomarkers information updated
- 21 May 2018 Status changed from recruiting to active, no longer recruiting.